Healthcare provider profile · identity verified

Leze Zagreda, D.O.

Internal Medicine · BRONX, NY · NPI 1811162837

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	778	231
Amlodipine Besylate	Amlodipine Besylate	682	228
Losartan Potassium	Losartan Potassium	346	110
Metformin Hcl	Metformin Hcl	327	107
Hydrochlorothiazide	Hydrochlorothiazide	283	94
Albuterol Sulfate Hfa	Albuterol Sulfate	281	90
Lisinopril	Lisinopril	277	88
Metoprolol Succinate	Metoprolol Succinate	256	85
Levothyroxine Sodium	Levothyroxine Sodium	226	59
Simvastatin	Simvastatin	223	65
Omeprazole	Omeprazole	203	71
Farxiga	Dapagliflozin Propanediol	189	45
Gabapentin	Gabapentin	163	50
Metformin Hcl Er	Metformin Hcl	159	49
Eliquis	Apixaban	153	40
Nifedipine Er	Nifedipine	151	41
Fluticasone Propionate	Fluticasone Propionate	138	48
Ozempic	Semaglutide	129	34
Montelukast Sodium	Montelukast Sodium	127	56
Furosemide	Furosemide	116	39
Rosuvastatin Calcium	Rosuvastatin Calcium	111	44
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	98	34
Trulicity	Dulaglutide	96	21
Metoprolol Tartrate	Metoprolol Tartrate	84	28
Famotidine	Famotidine	70	29
Carvedilol	Carvedilol	69	27
Januvia	Sitagliptin Phosphate	67	18
Tamsulosin Hcl	Tamsulosin Hcl	65	20
Valsartan	Valsartan	65	21
Alendronate Sodium	Alendronate Sodium	61	17
Clopidogrel	Clopidogrel Bisulfate	60	21
Pioglitazone Hcl	Pioglitazone Hcl	59	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	20
Alcohol Prep Pads	Alcohol Antiseptic Pads	57	24
Pravastatin Sodium	Pravastatin Sodium	56	23
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	55	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	55	19
Pantoprazole Sodium	Pantoprazole Sodium	53	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	52	16
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	51	17
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	42	16
Felodipine Er	Felodipine	41	14
Allopurinol	Allopurinol	39	12
Diclofenac Sodium	Diclofenac Sodium	39	16
Oxybutynin Chloride Er	Oxybutynin Chloride	38	suppressed
Ammonium Lactate	Ammonium Lactate	37	12
Jardiance	Empagliflozin	35	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	34	suppressed
Colchicine	Colchicine	33	suppressed
Enalapril Maleate	Enalapril Maleate	33	suppressed
Spironolactone	Spironolactone	33	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Ezetimibe	Ezetimibe	32	11
Finasteride	Finasteride	32	11
Hydralazine Hcl	Hydralazine Hcl	32	15
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	31	suppressed
Glimepiride	Glimepiride	31	suppressed
Tresiba Flextouch U-100	Insulin Degludec	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Meclizine Hcl	Meclizine Hcl	30	20
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	30	13
Potassium Chloride	Potassium Chloride	30	14
Pregabalin	Pregabalin	28	suppressed
Alprazolam	Alprazolam	27	suppressed
Atenolol	Atenolol	27	suppressed
Synthroid	Levothyroxine Sodium	26	13
Brilinta	Ticagrelor	25	suppressed
Ketoconazole	Ketoconazole	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Valacyclovir	Valacyclovir Hcl	25	suppressed
Arnuity Ellipta	Fluticasone Furoate	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Sertraline Hcl	Sertraline Hcl	21	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Irbesartan	Irbesartan	19	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	19
Trazodone Hcl	Trazodone Hcl	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Ramipril	Ramipril	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Mounjaro	Tirzepatide	16	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	16	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	15	suppressed
Glipizide Er	Glipizide	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Single Use Swab	Alcohol Antiseptic Pads	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	14	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Tradjenta	Linagliptin	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Verapamil Er	Verapamil Hcl	13	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	12	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	12	suppressed
Fosinopril Sodium	Fosinopril Sodium	12	suppressed
Lamotrigine	Lamotrigine	12	suppressed
Naproxen	Naproxen	12	11
Prednisone	Prednisone	12	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	12	suppressed
Xigduo Xr	Dapaglifloz Propaned/Metformin	12	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	11	suppressed
Baclofen	Baclofen	11	suppressed
Dapagliflozin	Dapagliflozin Propanediol	11	11
Fluocinonide	Fluocinonide	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Myrbetriq	Mirabegron	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Tresiba Flextouch U-200	Insulin Degludec	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error